IDEAYA Biosciences, Inc. (IDYA) financial statements (2022 and earlier)

Company profile

Business Address 7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments246,770283,58598,956
Cash and cash equivalents92,04672,03734,067
Short-term investments154,724211,54864,889
Receivables1,1031,877 
Other undisclosed current assets3,1233,1432,698
Total current assets:250,996288,605101,654
Noncurrent Assets
Operating lease, right-of-use asset3,8985,2055,057
Property, plant and equipment4,7634,2714,642
Long-term investments and receivables121,293 1,526
Long-term investments121,293 1,526
Restricted cash and investments106106106
Other noncurrent assets2918216
Total noncurrent assets:130,3519,66411,347
TOTAL ASSETS:381,347298,269113,001
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,4209,4695,732
Accounts payable2,100953709
Accrued liabilities12,3208,5165,023
Deferred revenue29,04027,613 
Debt  1,145
Other liabilities 1863
Other undisclosed current liabilities1,6991,540 
Total current liabilities:45,15938,6406,940
Noncurrent Liabilities
Long-term debt and lease obligation3,4825,1835,627
Operating lease, liability3,4825,1835,627
Liabilities, other than long-term debt31,19256,17234
Deferred revenue31,19256,160 
Other liabilities 1234
Total noncurrent liabilities:34,67461,3555,661
Total liabilities:79,83399,99512,601
Stockholders' equity
Stockholders' equity attributable to parent301,514198,274100,400
Common stock432
Additional paid in capital478,970325,250192,824
Accumulated other comprehensive income (loss)(712)765
Accumulated deficit(176,748)(126,986)(92,491)
Total stockholders' equity:301,514198,274100,400
TOTAL LIABILITIES AND EQUITY:381,347298,269113,001

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Revenues27,94119,538 
Gross profit:27,94119,538 
Operating expenses(78,209)(54,882)(44,271)
Operating loss:(50,268)(35,344)(44,271)
Nonoperating income5068492,296
Investment income, nonoperating  2,288
Net loss available to common stockholders, diluted:(49,762)(34,495)(41,975)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(49,762)(34,495)(41,975)
Comprehensive loss:(49,762)(34,495)(41,975)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(719)(58)96
Comprehensive loss, net of tax, attributable to parent:(50,481)(34,553)(41,879)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: